Cardiac
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF).
Study ID: Elevate-HF
Principal Investigator: Puvanalingam Ayyadurai, MD, FACC
Oncology
Lung
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cance Whose Tumors Express PD-L1
- Study ID: ARTEMIDE-Lung02
- Principal Investigator: Ivan Bustillo, M.D.
A Phase III Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completel Resected High-Risk Stage I Non-Small Cell Lung Cancer
- Study ID: INTerpath-014
- Principal Investigator: Ivan Bustillo, M.D.
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer (LU008)
- Study ID: NRG LU008
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants with Non-Small Cell Lung Cancer (INTerpath-002)
- Study ID: V940-002
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Environmental
A Pilot of a Randomized, Pragmatic Trial of Cancer-Directed Therapy Administration in the Patients’ Homes Versus in Clinic
- Study ID: CCBW
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Biorepository
The CARIS Biorepository Research Protocol: Breast Screening Blood Collection & Newly Diagnosed Pan-Cancer Cohorts
- Study ID: CARIS
- Principle Investigator: Grant Seeger, MD
Breast
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
- Study ID: MK2870-032
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery.
- Study ID: MK2870-012
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- Study ID: CCTG MA.39
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Prostate
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvaging Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy
- Study ID: NRG-GU008
- Principle Investigator: Grant Seeger, MD
Phase III Five Fraction Radiation for High-Risk Prostate Cancer (HIGH FIVE TRIAL)
- Study ID: NRG-GU013
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature
- Study ID: SWOG S2312
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Gastrointestinal
Colon Adjuvant Chemotherapy Based On Evaluation of Residual Disease (Circulate- North America)
- Study ID: NRG-GI008
- Principal Investigator: Grant Seeger, MD
- Status: Enrolling
Gynecologic
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Study ID: ECHO
- Principal Investigator: Collette Lessard, MD
- Status: Enrolling
